Werewolf Therapeutics (HOWL) Cash & Equivalents (2020 - 2026)

Werewolf Therapeutics has reported Cash & Equivalents for 7 years, with the latest figure at $22.0 million in Q2 2026.

• Cash & Equivalents for Q2 2026 came in at $22.0 million, down 71.65% year-over-year; the trailing twelve-month figure through Jun 2026 was $22.0 million (down 71.65% YoY), and the FY2025 annual result was $57.0 million, down 48.6% from the prior year.
• Cash & Equivalents fell to $22.0 million in Q2 2026, from $46.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $147.9 million in Q1 2023 and troughed at $22.0 million in Q2 2026.
• A 5-year average of $109.9 million and a median of $129.7 million in 2022 frame the typical range for Cash & Equivalents.
• The widest annual swing landed in 2022, when Cash & Equivalents surged 69.87%; it then tumbled 71.65% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $129.3 million in 2022, then grew by 3.89% to $134.3 million in 2023, then dropped by 17.38% to $111.0 million in 2024, then sank by 48.6% to $57.0 million in 2025, then slumped by 61.44% to $22.0 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $22.0 million in Q2 2026, $46.5 million in Q1 2026, and $57.0 million in Q4 2025.